Zhitong Financial APP News, minimally invasive Robot-B (02252) issued an announcement, the company and Biobot Surgical Pte.Ltd. Mona Lisa prostate puncture robot positioning system (Mona Lisa), a product of Shanghai Jiahang Robot Co., Ltd. (minimally invasive navigation robot), a joint venture in China, has completed all registered clinical trials. The registered clinical trial was conducted by Gulou Hospital affiliated to Medical College of Nanjing University, together with the first affiliated Hospital of Xi'an Jiaotong University and Subei people's Hospital. Mona Lisa has the advantages of stable operation, safe operation and smooth flow. It has obvious advantages over traditional manual puncture methods in operation safety, learning curve and puncture detection rate, and has great clinical value.

It is reported that the Mona Lisa is an innovative robot product in the percutaneous puncture track layout, which aims to assist doctors to perform prostate biopsy more safely, accurately, intelligently and efficiently. Relying on surgical robot and artificial intelligence technology, Mona Lisa can make programs through intelligent software to assist clinicians to better complete various operations, not only showing the 3D visual MRI- ultrasound fusion technology, but also its motion compensation and needle offset position compensation technology to further improve the accuracy of puncture surgery, reduce the rate of missed diagnosis, reduce the number of wounds, and reduce the pain of patients.

With the completion of this clinical enrollment, Mona Lisa has become the first prostate puncture robot in China to complete a registered clinical trial in the field of urology, and it is also a new breakthrough in the field of percutaneous puncture, marking a key step towards the advanced diagnosis and treatment of prostate cancer. The minimally invasive navigation robot plans to submit an application for registration of Mona Lisa to the State Drug Administration in the third quarter of 2022.